tiprankstipranks
Adynxx, Inc. (ADYX)
OTHER OTC:ADYX
US Market

Adynxx (ADYX) Stock Price & Analysis

60 Followers

ADYX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.02 - $0.02
Previous Close$0.02
Volume8.00
Average Volume (3M)N/A
Market Cap
$6.00
Enterprise Value$9.15M
Total Cash (Recent Filing)$331.00K
Total Debt (Recent Filing)$9.48M
Price to Earnings (P/E)N/A
Beta0.97
Nov 14, 2019
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.76
R-Squared0.00171
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.54
Enterprise Value/Gross Profit18.45
Enterprise Value/Ebitda-1.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ADYX FAQ

What was Adynxx, Inc.’s price range in the past 12 months?
Adynxx, Inc. lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
    What is Adynxx, Inc.’s market cap?
    Currently, no data Available
    When is Adynxx, Inc.’s upcoming earnings report date?
    Adynxx, Inc.’s upcoming earnings report date is Nov 14, 2019 which is 1629 days ago.
      How were Adynxx, Inc.’s earnings last quarter?
      Adynxx, Inc. released its earnings results on Aug 14, 2019. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.87.
        Is Adynxx, Inc. overvalued?
        According to Wall Street analysts Adynxx, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Adynxx, Inc. pay dividends?
          Adynxx, Inc. pays a Notavailable dividend of $1.05 which represents an annual dividend yield of N/A. See more information on Adynxx, Inc. dividends here
            What is Adynxx, Inc.’s EPS estimate?
            Adynxx, Inc.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Adynxx, Inc. have?
            Adynxx, Inc. has 5,808,000 shares outstanding.
              What happened to Adynxx, Inc.’s price movement after its last earnings report?
              Adynxx, Inc. reported an EPS of -$0.87 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Adynxx, Inc.?
                Currently, no hedge funds are holding shares in ADYX
                ---

                Adynxx Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Adynxx, Inc.

                Adynxx, Inc. is a clinical stage biopharmaceutical company. It engages in the manufacture, development, and sale of novel, disease-modifying products for the treatment of pain and inflammation. The company was founded by Julien Mamet in October 2007 and is headquartered in San Francisco, CA.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Aclaris Therapeutics
                Anika Therapeutics
                Avadel Pharmaceuticals
                Accelerate Diagnostics
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis